Prevention of spontaneous neu-expressing mammary tumor development in mice transgenic for rat protoneu by DNA vaccination

Gene Therapy

Volumn 8, Issue 1, 2001, Pages 75-79

  Pupa, S M ^a   Invernizzi, A M ^a   Forti, S ^a   Carlo, E Di ^b   Musiani, P ^b   Nanni, P ^c   Lollini, P L ^c   Meazza, R ^d   Ferrini, S ^d   Menard, S ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

Author keywords

Breast cancer; DNA vaccination; Proto neu transgenic mice

Indexed keywords

COMPLEMENTARY DNA; DNA VACCINE; ONCOPROTEIN; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; BREAST CARCINOGENESIS; BREAST TUMOR; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOMEGALOVIRUS; DNA SEQUENCE; EXPRESSION VECTOR; FEMALE; GENE OVEREXPRESSION; GENE TARGETING; GENETIC ENGINEERING; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; INFLAMMATION; MOUSE; MOUSE MAMMARY TUMOR ONCOVIRUS; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; PROMOTER REGION; PROTO ONCOGENE; RAT; T LYMPHOCYTE; TRANSGENIC MOUSE; TUMOR GROWTH;

AGE FACTORS; ANIMALS; CANCER VACCINES; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; IMMUNIZATION SCHEDULE; LYMPHOCYTE CULTURE TEST, MIXED; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; NEOPLASM PROTEINS; RATS; RECEPTOR, ERBB-2; VACCINES, DNA;

ANIMALIA; CYTOMEGALOVIRUS; MAMMARY TUMOR ONCOVIRUS; MAMMARY TUMOR VIRUS; MOUSE MAMMARY TUMOR VIRUS; MUS MUSCULUS; ONCOVIRINAE; TUMOR VIRUS;

EID: 17744399231     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301360     Document Type: Article

References (33)

1. Role of HER2 gene overexpression in breast carcinoma
2. Antibody response against the c-erbB-2 oncoprotein in breast carcinoma patients
3. High titer HER-2/neu protein specific antibody immunity can be detected in patients with early stage breast cancer
4. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines
5. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide
6. Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, an oncogenic self-protein
7. HER-2/neu protein: A target for antigenspecific immunotherapy of human cancer
8. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice
9. Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice
10. Targeting HER-2/neu for active-specific immunotherapy in a mouse model of spontaneous breast cancer
11. Autoantibody to p185erbB2/neu oncoprotein by vaccination with xenogeneic DNA
12. DNA vaccines encoding full-length or truncated neu induce protective immunity against neu-expressing mammary tumors
13. Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA
14. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease
15. DNA vaccines encoding full-length or truncated neu induce protective immunity against neu-expressing mammary tumors
16. neu protein is required for tumor and anchorage-independent growth, not for cell proliferation of transgenic mammary carcinoma
17. Genetic immunization is a simple method for eliciting an immune response
18. Intradermal gene immunization: The possible role of DNA uptake in the induction of cellular immunity to viruses
19. Vaccination against tuberculosis by DNA injection
20. Protection against leishmaniasis by injection of DNA encoding a major surface glycoprotein, gp63, of L. major
21. Suppressive vaccination with DNA encoding a variable region gene of the T-cell receptor prevents autoimmune encephalomyelitis and activates Th2 immunity
22. Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization
23. Immune response to a carcinoembryonic antigen polynucleotide vaccine
24. Intramuscular immunisation with MUC1 cDNA can protect C57 mice challenged with MUC1-expressing syngeneic mouse tumour cells
25. Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine
26. DNA vaccination against the ovarian carcinoma-associated antigen folate receptor (FR)α induces CTL and antibody responses in mice
27. Genetic vaccination against the melanocyte lineage-specific antigen gp100 induces cytotoxic T lymphocyte-mediated tumor protection
28. Ability of systemic interleukin-12 to hamper progressive stages of mammary carcinogenesis in HER2/neu transgenic mice
29. Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice
30. The role of CpG motifs in innate immunity
31. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine
32. HER2 and growth inhibition of cells with HER2/neu gene amplification
33. Increased expression of c-erbB-2 in hormone-dependent breast cancer cells inhibits cell growth and induces differentiation